For far too long there has been a gap between payers and diagnostic companies where diagnostic technology has been characterized as “expensive and unnecessary”, because it has been poorly understood, undervalued and underutilized. Alva10 was established in response to this divide. With years of experience in pharmaceutical and diagnostic companies, Founders Hannah Mamuszka and Lena Chaihorsky built a team and company dedicated to narrowing that knowledge gap. Armed with and driven by knowledge, curiosity and a passion to innovate the industry, Alva10 set out to redesign the healthcare system while restructuring current spiraling healthcare spend. Read more about how Alva10 was founded here.
Alva10 reduces ineffective therapeutic spend through customized solutions that provide advanced knowledge of patients’ ability to respond to costly therapies before they are given. Through our proprietary model M.A.T.E. we restructure the relationship between health insurance payers and Precision Medicine diagnostic companies. The result of this new way of doing business is a broad range of completely novel healthcare tools that directly solve the large clinical and economic challenges for payers and providers.
In partnering with us, we enable our payer and provider partners to source innovations for their greatest needs. Our industry-leading asset of Precision Medicine technology curation ensures that those partners receive the best-in-class tool for their particular problem.
ABOUT ALVA10
In the USA, our healthcare system readily pays for drugs and procedures, but not for the diagnostics that can tell us whether those will work for the individual patient. The concept of ‘Precision Medicine’—using diagnostic tools, combined with other patient health information to make informed, patient-specific decisions about treatment—requires that diagnostics be available in the market, used by physicians, and reimbursed by payers in order to impact and improve patient care.
Executive TEAM
Mike Fried
Blake Long
Lena Chaihorsky
Hannah Mamuszka
Mike Fried
Blake Long
Lena Chaihorsky
Hannah Mamuszka
Executive TEAM
Hannah Mamuszka
Hannah Mamuszka
Hannah Mamuszka is Founder and Chief Executive Officer at Alva10, which she founded in 2015 to spur change in healthcare to allow more patients better access to diagnostic technology. Hannah’s career has spanned the laboratory and business sides of healthcare in both the pharma and diagnostics industries. Prior to Alva10, Hannah was VP of Exosome Diagnostics (acquired by BioTechne), where she led some of the earliest deals in the liquid biopsy space. Earlier in her career, she was Global Director of Pharmaceuticals Services for Oncotech, and then by acquisition, Exiqon (acquired by QIAGEN), where she built the Pharmaceutical Services and Companion Diagnostics business in the US, Europe, and ROW. Prior to her time in diagnostics, she worked on the IND submission for VelcadeTM at Millennium Pharmaceuticals (acquired by Takeda). She started her laboratory career at the National Institutes of Health, holding laboratory positions in both the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Disease (NIAID). Hannah is a frequent speaker and writer on how to drive change in healthcare, and is on the editorial board for the Journal of Precision Medicine, where she also writes a regular column on the challenges of implementing change in medicine. Hannah serves on the Board of Directors for Bionano Genomics (BNGO) and a diagnostic company in stealth mode.
Hannah Mamuszka - Founder & CEO
Bio
Lena Chaihorsky
Lena Chainhorsky
LENA CHAIHORSKY - CO-FOUNDER & VP PAYER INNOVATION
Lena is the co-founder and Vice President of Payer Innovation at Alva10. With a background in biology and mathematics from Tufts, she is a skilled healthcare executive with a proven track record of developing and executing value based reimbursement strategies for diagnostics companies. Lena has extensive leadership experience in sales, national contracting, and all aspects of reimbursement within start-up and global companies, most recently AmniSure and QIAGEN. Lena also contributes to Alva10’s public speaking and writing efforts, leveraging her unique perspective on payer business and innovation models and their intersections with the diagnostics industry. Her work on commercial approaches to health economics data analysis led to her appointment as co-chair of the World Economic Forum’s workgroup dedicated to the economics of rare disease data federations in 2019. She is active within the Tufts Alumni Career Networking Community, and both a mentor and mentee within the HLTH Foundation’s CSweetener , a 501(c) 3 charity working toward healthcare equality, diversity and access by empowering women to seek and obtain mentorship from industry leaders.
Bio
Blake Long
Blake Long
Blake believes that precision medicine now requires innovation in both clinical science and health care systems to achieve precision delivery. He is dedicated to developing the necessary entrepreneurial ecosystem from the clinical, health economic and strategic capital perspectives. Blake was previously the Chief Medical Officer for Sapere Bio and for Echo Health Ventures, the venture investment group of BlueCross BlueShield of NC and Cambia Health Solutions. Prior to Echo, Blake served for 20 years as a practicing pediatric cardiologist at Savannah Children’s Heart Center and as a clinical professor at Mercer University School of Medicine. He earned his BA and MD from Duke University, and then completed his clinical training at Walter Reed Army Medical Center and Duke Medical Center. He received his MBA from Duke's Fuqua School of Business in 2015, and now is an Adjunct Professor at Fuqua in the Health Sector Management Program.
BLAKE LONG, MD MBA - CHIEF MEDICAL OFFICER
Bio
Mike Fried
Mike Fried
Mike has 20+ years’ experience developing and innovating new analytics processes to support strategic decisions around healthcare, retail analytics and market research. With a background in aerospace engineering, Mike has applied his mathematical skills to the corporate and consulting environments developing business intelligence products, building analytics teams and growing companies. As part of the JetBlue Airways startup team, Mike guided the financial analysis, market research and revenue strategy in a high growth fast paced environment. Transitioning to consulting, Mike founded a digital analytics practice working within the travel and e-commerce industries to provide analytics solutions and advanced insights through demand modeling, forecasting and pricing.
Mike has recently taken his passion for analytics to the healthcare industry by joining Alva10 in 2019 and completing a Master’s Degree in Biomedical and Health Informatics at the University of North Carolina.
MIKE FRIED - VP OF DATA ANALYTICS & BUSINESS INTELLIGENCE
Bio
As a small company, we hire based on team fit and passion. We are growing and looking to hire people with a passion to change and improve healthcare. Interested to learn more? Send us a message HERE.
Want to join our team?
As a small company, we hire based on team fit and passion. We are growing and looking to hire people with a passion to change and improve healthcare.
Interested to learn more?
Send us a message HERE.
Hannah has spent her 20+ year career in diagnostics - both in pharma and at diagnostics companies - in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data.
Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Advisory Member - Title
Bio
Hannah has spent her 20+ year career in diagnostics - both in pharma and at diagnostics companies - in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data.
Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Advisory Member - Title
Bio
Hannah has spent her 20+ year career in diagnostics - both in pharma and at diagnostics companies - in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data.
Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Advisory Member - Title
Bio
Hannah has spent her 20+ year career in diagnostics - both in pharma and at diagnostics companies - in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data.
Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Advisory Member - Title
Bio
Hannah has spent her 20+ year career in diagnostics - both in pharma and at diagnostics companies - in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data.
Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Advisory Member - Title
Bio
Hannah has spent her 20+ year career in diagnostics - both in pharma and at diagnostics companies - in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data.
Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
